World Health Organization, 2024-11-21: WHO's current fact sheet states the recommended mass drug administration regimens for lymphatic filariasis, including the three-drug regimen of ivermectin, DEC and albendazole (IDA).
ivermectin (200 mcg/kg) together with diethylcarbamazine citrate (DEC) (6 mg/kg) and albendazole (400 mg) in countries without onchocerciasis and where other programmatic conditions are met.
World Health Organization, 2024-11-21: WHO's current fact sheet states the recommended mass drug administration regimens for lymphatic filariasis, including the three-drug regimen of ivermectin, DEC and albendazole (IDA). Page prints 21 November 2024. Record field transcribed from the 'Treatment' section bullet list of recommended MDA regimens (not continuous prose beyond the bullet itself). The same section lists ivermectin 200 mcg/kg with albendazole 400 mg for countries with onchocerciasis, and DEC 6 mg/kg plus albendazole 400 mg where onchocerciasis is absent. WHO notes 657 million people in 39 countries still required preventive chemotherapy in 2023 and 9.7 billion cumulative treatments delivered since 2000. Study type: regulatory record.
